共 314 条
[1]
Jennette JC(2013)2012 revised International Chapel Hill consensus conference nomenclature of vasculitides Arthritis Rheum 65 1-11
[2]
Falk RJ(2021)CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update J Rheumatol 48 555-566
[3]
Bacon PA(2021)2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheumatol 73 1366-1383
[4]
Basu N(2018)Outcomes and compliance with standards of care in anti-neutrophil cytoplasmic antibody-associated vasculitis-insights from a large multiregion audit Rheumatol Adv Pract 2 rky025-2141
[5]
Cid MC(2018)Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis Clin Rheumatol 37 2133-651
[6]
Ferrario F(2017)Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study Mod Rheumatol 27 646-1160
[7]
Flores-Suarez LF(2015)Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Rheumatology (Oxford) 54 1153-405
[8]
Gross WL(2018)Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study BMC Nephrol 19 138-2076
[9]
Guillevin L(2019)Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial Ann Rheum Dis 78 399-61
[10]
Hagen EC(2018)Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large national claims database Arthritis Rheumatol 70 2067-1059